Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693830 · ClinicalTrials.gov registry record · NA
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
A NA study of Lymphoma and Diffuse Large B Cell Lymphoma, sponsored by Hua-Jay J Cherng, MD.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06693830 is a NA study of Lymphoma and Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Hua-Jay J Cherng, MD. The registered enrollment target is 40 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06693830, a NA study of Lymphoma and Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Hua-Jay J Cherng, MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL), and 2) evaluate the outcomes of participants with undetectable ctDNA in the middle of treatment who receive a shortened course of chemotherapy. There are no investigational drug agents to be administered in this study. The investigational assay, phased variant enrichment and detection sequencing (PhasED-seq) will be used to guide de-escalation of standard-of-care therapy for newly diagnosed DLBCL. The PhasED-seq assay has not yet been approved by the Food and Drug Administration (FDA).
Conditions Studied
Interventions
- OTHER Standard of Care Treatment
- DEVICE Phased Variant Enrichment and Detection Sequencing (PhasED-seq)
- OTHER De-escalated Treatment
Study Locations (1)
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-12-11 |
| Est. Completion | 2029-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06693830
The ClinicalTrials.gov registry entry for NCT06693830 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The listed sponsor is Hua-Jay J Cherng, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care Treatment is the first listed.
NCT06693830 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06693830 about?
NCT06693830 is a clinical study titled "ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL". The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL), and 2) evaluate the outcomes of participants with undetectable ctDNA in the middle of treatme...
What is the current status of trial NCT06693830?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-12-11. Estimated completion is 2029-12.
What conditions does trial NCT06693830 study?
This clinical trial studies the following conditions: Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell, High Grade B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.
What interventions are being tested in trial NCT06693830?
The interventions under investigation include: Standard of Care Treatment (OTHER), Phased Variant Enrichment and Detection Sequencing (PhasED-seq) (DEVICE), De-escalated Treatment (OTHER).
Who is sponsoring clinical trial NCT06693830?
This trial is sponsored by Hua-Jay J Cherng, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693830 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.